89bio, Inc.
General ticker "ETNB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2B (TTM average)
89bio, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 0.1%: low 14.83$, high 14.86$
Factors to consider:
- Total employees count: 93 (+32.9%) as of 2024
- Top business risk factors: Dependency on single product candidate, High R&D costs, Clinical trial uncertainties, Regulatory and compliance, Manufacturing risks
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.29$, 11.54$]
- 2025-12-31 to 2026-12-31 estimated range: [4.30$, 11.15$]
Financial Metrics affecting the ETNB estimates:
- Negative: with PPE of -2.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -45.16 <= 0.85
- Positive: Shareholder equity ratio, % of 83.73 > 62.86
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.65 <= 0.71
Short-term ETNB quotes
Long-term ETNB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $102.25MM | $151.20MM | $384.66MM |
| Operating Income | $-102.25MM | $-151.20MM | $-384.66MM |
| Non-Operating Income | $0.24MM | $12.88MM | $18.27MM |
| Interest Expense | $1.92MM | $4.79MM | $5.29MM |
| R&D Expense | $80.80MM | $122.23MM | $345.04MM |
| Income(Loss) | $-102.01MM | $-138.32MM | $-366.39MM |
| Taxes | $0.02MM | $3.87MM | $0.69MM |
| Profit(Loss)* | $-102.03MM | $-142.19MM | $-367.08MM |
| Stockholders Equity | $151.83MM | $536.31MM | $400.79MM |
| Assets | $196.82MM | $596.27MM | $478.69MM |
| Operating Cash Flow | $-81.09MM | $-129.19MM | $-367.82MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.01MM |
| Investing Cash Flow | $-33.94MM | $-123.02MM | $-40.86MM |
| Financing Cash Flow | $117.83MM | $513.11MM | $218.59MM |
| Earnings Per Share** | $-2.93 | $-2.00 | $-3.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.